Team:Edinburgh/ethics(legislationissues)

From 2009.igem.org

(Difference between revisions)
 
(25 intermediate revisions not shown)
Line 89: Line 89:
border-top:6px solid #CA9A38;
border-top:6px solid #CA9A38;
border-bottom:6px solid #CA9A38;
border-bottom:6px solid #CA9A38;
 +
}
 +
 +
#Upgradebox {
 +
background-color:#dae7b4;
 +
        float:left;
 +
width:160px;
 +
margin-top:320px;
 +
        border-top:6px solid #CA9A38;
 +
        border-bottom:6px solid #CA9A38;
 +
        font-size:11px;
 +
        font-family:Arial;
 +
        color:#556B2F;
 +
}
 +
 +
#Upgradenote {
 +
padding:5%;
}
}
Line 99: Line 115:
#contentmenu {
#contentmenu {
         margin-bottom:30px;
         margin-bottom:30px;
-
         margin-left:82px;
+
         margin-left:251px;
text-decoration: none
text-decoration: none
}
}
Line 108: Line 124:
         margin-bottom:2px;
         margin-bottom:2px;
background-color: #e5e7e2;
background-color: #e5e7e2;
-
height:1050px;
+
height:3550px;
         width:795px;
         width:795px;
-
         font-size:11px;
+
         font-size:12px;
         text-align:justify;
         text-align:justify;
}
}
Line 184: Line 200:
<div id=main>
<div id=main>
<div id=leftspace>
<div id=leftspace>
 +
                  <div id="Upgradebox">
 +
            <div id="Upgradenote" align="left">
 +
                      Our WIKI is best viewed with (click title):<br /><br />
 +
                      * <a target="_blank" style="color:#00008B;text-decoration:underline;" href="http://www.microsoft.com/windows/Internet-explorer/default.aspx">Internet Explorer 8</a> <br />
 +
                      * <a target="_blank" style="color:#00008B;text-decoration:underline;" href="http://www.mozilla.com/en-US/">Firefox 3</a><br />
 +
                      * <a target="_blank" style="color:#00008B;text-decoration:underline;" href="http://get.adobe.com/flashplayer/">Adobe Flash Player 10</a> <br /><br />
 +
                      If you encounter any visual problems please upgrade your browser to the latest version in order to get the most out of our WIKI. Thank you!
 +
                    </div>
 +
                  </div>
</div>
</div>
<div id=mainmenu>
<div id=mainmenu>
-
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28introduction%29"> Introduction </a> </div>  
+
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28publicperception%29"> Public Perception </a> </div>
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28legislationissues%29"> Legislation Issues </a> </div>  
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28legislationissues%29"> Legislation Issues </a> </div>  
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28biosafety%29"> Biosafety </a> </div>
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28biosafety%29"> Biosafety </a> </div>
-
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28religiousperception%29"> Religious Perception </a> </div>
+
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28summary%29"> Democs Card Game</a> </div>   
-
<div id=menuitem <a href="https://2009.igem.org/Team:Edinburgh/ethics%28publicperception%29"> Public Perception </a> </div>
+
-
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28surveyandconclusions%29"> Survey and Conclusions </a> </div>
+
-
<div id=menuitem >  <a href="https://2009.igem.org/Team:Edinburgh/ethics%28summary%29"> Summary (Pro and Contras) </a> </div>
+
</div>
</div>
<div id=Edinburghcontainer>
<div id=Edinburghcontainer>
Line 198: Line 220:
<ul id="nav" class="dropdown dropdown-horizontal">
<ul id="nav" class="dropdown dropdown-horizontal">
  <li><a href="https://2009.igem.org/Team:Edinburgh">Home</a></li>
  <li><a href="https://2009.igem.org/Team:Edinburgh">Home</a></li>
-
 
-
<li><a href="https://2009.igem.org/Team:Edinburgh/projectmain%28overall%29" class="dir">Top View</a>
 
-
  <ul>
 
-
  <li><a href="https://2009.igem.org/Team:Edinburgh/projectmain%28overall%29">Overall Description</a></li>
 
-
  <li><a href="https://2009.igem.org/Team:Edinburgh/projectmain%28motivationl%29">Motivation</a></li>
 
-
  <li><a href="https://2009.igem.org/Team:Edinburgh/projectmain%28whywediffer%29">Why We Differ?</a></li>
 
-
  <li><a href="https://2009.igem.org/Team:Edinburgh/projectmain%28glanceatthefuture%29">Glance At The Future</a></li>
 
-
  <li><a href="https://2009.igem.org/Team:Edinburgh/projectmain%28references%29">References</a></li>
 
-
  </ul>
 
-
  </li>
 
   <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28overalldescription%29" class="dir">Biology</a>
   <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28overalldescription%29" class="dir">Biology</a>
   <ul>
   <ul>
     <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28overalldescription%29">Overall Description and Design</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28overalldescription%29">Overall Description and Design</a></li>
 +
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28tntsensing%29">TNT-Sensing Pathway</a></li>
 +
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28nitritenitratesensing%29">Nitrite/Nitrate-Sensing Pathway</a></li>
 +
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28biobricks%29">Biobrick Parts</a></li>
 +
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28results%29">Results</a></li>
 +
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28solvedproblems%29">Problem Solving and Tips</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28materialsandmethods%29">Materials and Methods</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28materialsandmethods%29">Materials and Methods</a></li>
-
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28biobricks%29">Biobricks</a></li>
 
-
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28solvedproblems%29">Problem Solving and Tips</a></li>
 
-
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28results%29">Results</a></li>
 
-
    <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28glanceatthefuture%29">Future Work</a></li>
 
     <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28references%29">References</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/biology%28references%29">References</a></li>
   </ul>
   </ul>
Line 228: Line 241:
     <li><a href="https://2009.igem.org/Team:Edinburgh/reallifeapplication%28scaleup%29">Scale Up</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/reallifeapplication%28scaleup%29">Scale Up</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/modelling%28results%29">Results</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/modelling%28results%29">Results</a></li>
-
    <li><a href="https://2009.igem.org/Team:Edinburgh/modelling%28glanceatthefuture%29">Glance At the Future</a></li>
 
     <li><a href="https://2009.igem.org/Team:Edinburgh/modelling%28references%29">References</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/modelling%28references%29">References</a></li>
   </ul>
   </ul>
   </li>
   </li>
-
   <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28introduction%29" class="dir">Underlying Philosophy</a>
+
   <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28publicperception%29" class="dir">Underlying Philosophy</a>
     <ul>
     <ul>
-
     <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28introduction%29">Introduction</a></li>
+
     <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28publicperception%29">Public Perception</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28legislationissues%29">Legislation issues</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28legislationissues%29">Legislation issues</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28biosafety%29">Biosafety</a></li>
     <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28biosafety%29">Biosafety</a></li>
-
    <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28religiousperception%29">Religious Perception</a></li>
+
     <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28summary%29">DEMOCS Card Game</a></li>
-
    <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28publicperception%29">Public Perception</a></li>
+
-
    <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28surveyandconclusions%29">Survey and Conclusions</a></li>
+
-
     <li><a href="https://2009.igem.org/Team:Edinburgh/ethics%28summary%29">Summary (Synthetic Bilogy Pro and Contras)</a></li>
+
     </ul>
     </ul>
   </li>
   </li>
-
   <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28introduction%29" class="dir">New Informatics</a>
+
   <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28introduction%29" class="dir">Informatics</a>
     <ul>
     <ul>
       <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28introduction%29">Introduction</a></li>
       <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28introduction%29">Introduction</a></li>
-
      <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28conceptsandtechnology%29">Concepts and Technologies</a></li>
 
       <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28globetutorial%29">Globe Tutorial</a></li>
       <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28globetutorial%29">Globe Tutorial</a></li>
       <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28igemwikhacks%29">iGEM WIKI Hacks</a></li>
       <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28igemwikhacks%29">iGEM WIKI Hacks</a></li>
-
       <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28conclusions%29">Conclusions</a></li>
+
       <li><a href="https://2009.igem.org/Team:Edinburgh/newinformatics%28conclusions%29">Blog Entry</a></li>
     </ul>
     </ul>
   </li>
   </li>
-
 
+
 
-
  <li><a href="https://2009.igem.org/Team:Edinburgh/results">Results</a></li>
+
   <li><a href="https://2009.igem.org/Team:Edinburgh/Notebook">Notebook</a></li>
   <li><a href="https://2009.igem.org/Team:Edinburgh/Notebook">Notebook</a></li>
    
    
-
   <li><a href="https://2009.igem.org/Team:Edinburgh/team%28teamintroduction%29" class="dir">Team</a>
+
   <li><a href="https://2009.igem.org/Team:Edinburgh/team%28teammembers%29" class="dir">Team</a>
   <ul>
   <ul>
-
<li><a href="https://2009.igem.org/Team:Edinburgh/team%28teamintroduction%29">Team Introduction</a></li>
 
-
<li><a href="https://2009.igem.org/Team:Edinburgh/team%28edinburghuniversity%29">Edinburgh University</a></li>
 
<li><a href="https://2009.igem.org/Team:Edinburgh/team%28teammembers%29">Team Members</a></li>
<li><a href="https://2009.igem.org/Team:Edinburgh/team%28teammembers%29">Team Members</a></li>
<li><a href="https://2009.igem.org/Team:Edinburgh/team%28advisors%29">Advisors</a></li>
<li><a href="https://2009.igem.org/Team:Edinburgh/team%28advisors%29">Advisors</a></li>
<li><a href="https://2009.igem.org/Team:Edinburgh/team%28supervisors%29">Supervisors</a></li>
<li><a href="https://2009.igem.org/Team:Edinburgh/team%28supervisors%29">Supervisors</a></li>
-
        <li><a href="https://2009.igem.org/Team:Edinburgh/team%28our message%29">Our Message</a></li>
 
         <li><a href="https://2009.igem.org/Team:Edinburgh/team%28gallery%29">Gallery</a></li>
         <li><a href="https://2009.igem.org/Team:Edinburgh/team%28gallery%29">Gallery</a></li>
         <li><a href="https://2009.igem.org/Team:Edinburgh/team%28contacts%29">Contacts</a></li>
         <li><a href="https://2009.igem.org/Team:Edinburgh/team%28contacts%29">Contacts</a></li>
Line 280: Line 284:
<div id="abstarct" style="background-color:#e4f5ca;border:1px solid #595151;width:755px;height:220px;margin-top:10px;margin-left:20px;font-size:11px;text-align:justify;padding-left:5px;padding-right:5px;padding-top:5px;padding-bottom:5px;">
<div id="abstarct" style="background-color:#e4f5ca;border:1px solid #595151;width:755px;height:220px;margin-top:10px;margin-left:20px;font-size:11px;text-align:justify;padding-left:5px;padding-right:5px;padding-top:5px;padding-bottom:5px;">
-
<b> Abstract </b> <br /><br />
+
<b> Personal note </b> <br /><br />
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent nec nisi nec elit volutpat sollicitudin. Sed cursus venenatis egestas. In mollis vehicula dictum. Sed id lacus vitae tortor commodo pharetra porttitor ut purus. Nullam euismod urna at felis accumsan sit amet viverra leo fermentum. Phasellus ac molestie sapien. In in neque purus. Cras eget lorem arcu. Aliquam ornare tellus vel nisi commodo molestie. Aliquam aliquet magna nisl. Quisque velit nulla, adipiscing ut sagittis id, luctus viverra leo. Nam nunc nisl, euismod eu dignissim nec, eleifend ut augue. Phasellus tempor condimentum ipsum, ut molestie lorem suscipit vel. Nulla luctus turpis eget neque facilisis eget sodales ante tincidunt. Praesent congue lobortis mollis. Maecenas non augue id mi dignissim luctus. Donec quis volutpat lectus. Mauris condimentum sodales luctus.
+
I believe that science has a nasty trait of being condescending towards the general public. We, as scientists, often neglect our responsibilities and forget that we have a duty to involve others in our findings, from an political point of view (as it is the taxpayer who pays for basic research we conduct), as well as from an ethical point of view. I strongly believe that by keeping others in the dark we widen the gap between science and the general public. Of course, one could argue that the public has already had access to all our findings through journals and science articles—but I argue that this very claim is where the condescendence begins. A great part of involving people in what we do is the way we present scientific discoveries to them — a great example of good public communication of science would be an epigenetics pamphlet issued by Cancer Research UK I've recently seen. Although not everyone will be interested in it, we know that we have done our bit to make it accessible, and that is a very rewarding accomplishment in itself .
-
Nulla nec mauris sapien, eget gravida quam. Fusce vulputate risus eget diam elementum vel mattis nisi sagittis. Vivamus eget enim a nisl imperdiet aliquet commodo eget turpis. Aliquam nec mi ac neque tincidunt facilisis fringilla at sapien. Praesent in justo vel turpis hendrerit suscipit. Nullam nec magna leo, sed vulputate quam. Aliquam sollicitudin hendrerit erat at eleifend. Vivamus tincidunt felis vitae metus suscipit non volutpat neque tempus. Phasellus sagittis accumsan tellus, vitae pharetra ligula rhoncus vitae.
+
<br /><br />
 +
 
 +
<font color="green" style="float:right"> Julia </font>
</div>
</div>
-
<img src="https://static.igem.org/mediawiki/2009/3/3b/EdinburghParagraphMarker.jpg" style="margin-left:-5px;margin-top:20px;">
+
<img src="https://static.igem.org/mediawiki/2009/c/cc/ReleaseOfGenetically.jpg" style="margin-left:-5px;margin-top:20px;">
<div id="text" style="margin-left:20px;margin-top:10px;padding-bottom:15px;">
<div id="text" style="margin-left:20px;margin-top:10px;padding-bottom:15px;">
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent nec nisi nec elit volutpat sollicitudin. Sed cursus venenatis egestas. In mollis vehicula dictum. Sed id lacus vitae tortor commodo pharetra porttitor ut purus. Nullam euismod urna at felis accumsan sit amet viverra leo fermentum. Phasellus ac molestie sapien. In in neque purus. Cras eget lorem arcu. Aliquam ornare tellus vel nisi commodo molestie. Aliquam aliquet magna nisl. Quisque velit nulla, adipiscing ut sagittis id, luctus viverra leo. Nam nunc nisl, euismod eu dignissim nec, eleifend ut augue. Phasellus tempor condimentum ipsum, ut molestie lorem suscipit vel. Nulla luctus turpis eget neque facilisis eget sodales ante tincidunt. Praesent congue lobortis mollis. Maecenas non augue id mi dignissim luctus. Donec quis volutpat lectus. Mauris condimentum sodales luctus.
+
Since our system requires genetically modified bacteria to be released into the environment there are certain legal issues that must be reviewed before we can do this. In the UK the release of genetically modified organisms, GMO’s is covered under “The Genetically Modified Organisms (Deliberate Release) Regulations 2002”. This legislation covers all releases that are not subject to higher, more stringent legislation for example GM medicines. In the USA there is less clearly defined legislation for the release of GMO’s, which is still covered by the laws which were first adopted in 1986 to regulate against the products of biotechnology. This is done using federal agencies in the “Coordinated Framework for Regulation of Biotechnology”<sup>1</sup>
 +
</div>
-
Nulla nec mauris sapien, eget gravida quam. Fusce vulputate risus eget diam elementum vel mattis nisi sagittis. Vivamus eget enim a nisl imperdiet aliquet commodo eget turpis. Aliquam nec mi ac neque tincidunt facilisis fringilla at sapien. Praesent in justo vel turpis hendrerit suscipit. Nullam nec magna leo, sed vulputate quam. Aliquam sollicitudin hendrerit erat at eleifend. Vivamus tincidunt felis vitae metus suscipit non volutpat neque tempus. Phasellus sagittis accumsan tellus, vitae pharetra ligula rhoncus vitae.
+
<img src="https://static.igem.org/mediawiki/2009/f/fb/UkLegislation.jpg" style="margin-left:-5px;margin-top:20px;">
 +
 
 +
<div id="text" style="margin-left:20px;margin-top:10px;padding-bottom:15px;">
 +
 
 +
As previously stated the UK legislation on release of GMO’s is covered by “The Genetically Modified Organisms (Deliberate Release) Regulations 2002”. This legislation sets out all the steps which must be taken before any permission will be granted for the release of GMO’s. The legislation is split into 2 types of release, either a Part B or Part C release. A Part B release is one where the GMO is released for a non commercial application including for research purposes and a Part C release is for a commercial application. The decision making processes for these releases are slightly different with Part B applications being dealt with by the member EU state, in this case the UK,  while Part C releases are dealt with at EU level, while also ensuring that local regulations are met. This means that all the countries in the EU have a say in any commercial release of GMO’s.
<br /><br />
<br /><br />
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent nec nisi nec elit volutpat sollicitudin. Sed cursus venenatis egestas. In mollis vehicula dictum. Sed id lacus vitae tortor commodo pharetra porttitor ut purus. Nullam euismod urna at felis accumsan sit amet viverra leo fermentum. Phasellus ac molestie sapien. In in neque purus. Cras eget lorem arcu. Aliquam ornare tellus vel nisi commodo molestie. Aliquam aliquet magna nisl. Quisque velit nulla, adipiscing ut sagittis id, luctus viverra leo. Nam nunc nisl, euismod eu dignissim nec, eleifend ut augue. Phasellus tempor condimentum ipsum, ut molestie lorem suscipit vel. Nulla luctus turpis eget neque facilisis eget sodales ante tincidunt. Praesent congue lobortis mollis. Maecenas non augue id mi dignissim luctus. Donec quis volutpat lectus. Mauris condimentum sodales luctus.
+
Before any GMO can be released to the environment it must go through the following stages of regulation :
 +
<br /><br />
 +
• An application must be submitted to the Secretary of State.<br />
 +
• The application will then be scrutinised by independent scientific experts to ensure the safety standards of directive 2001/18 are met<br />
 +
• A public consultation is held<br />
 +
• A decision is taken by the regulators based on the expert advice and the public representations. If consent is granted, a list of conditions for the release will be included stating how the GMO may/may not be used.<br />
 +
• If the GMO is released, it will be monitored and if any new risks are discovered then the regulators have the right to amend of revoke the consent.<br /><br />
-
Nulla nec mauris sapien, eget gravida quam. Fusce vulputate risus eget diam elementum vel mattis nisi sagittis. Vivamus eget enim a nisl imperdiet aliquet commodo eget turpis. Aliquam nec mi ac neque tincidunt facilisis fringilla at sapien. Praesent in justo vel turpis hendrerit suscipit. Nullam nec magna leo, sed vulputate quam. Aliquam sollicitudin hendrerit erat at eleifend. Vivamus tincidunt felis vitae metus suscipit non volutpat neque tempus. Phasellus sagittis accumsan tellus, vitae pharetra ligula rhoncus vitae.
+
There are slight differences in the way that Part B and Part C releases are dealt with and these are shown in the following Gantt charts shown in Figure 1 and Figure 2.
<br /><br />
<br /><br />
 +
<center><img src="https://static.igem.org/mediawiki/2009/e/e4/Gantchart1.jpg"></center>
 +
<center>Figure 1: Gantt chart showing the different stages required before a Part B release will be approved.</center>
 +
 +
<br /><br />
 +
<center><img src="https://static.igem.org/mediawiki/2009/d/d0/Gantchart2.jpg"></center>
 +
<center>Figure 2: Gantt chart showing the different stages required before a Part C release will be approved.</center>
 +
 +
<br /><br />
 +
 +
Since one of the steps in this both Part B and Part C releases require a public consultaion to be held before any approval would be made we decided that it would be interesting to conduct our own survey to find out the public perception on both our system and on synthetic biology in general. The survey results can be found <a href="https://2009.igem.org/Team:Edinburgh/ethics%28publicperception%29">here</a>.
 +
 +
<br /><br />
 +
 +
From the information given on the “Department for Environment, Food and Rural Affairs”, DEFRA, website , no release of GMO bacteria for a similar purpose to ours had been approved however there was no information to indicate if any attempt had been made. This is to say that we are unsure about how the UK authorities would react to our system.
-
<div id="left" style="width:50%">
 
-
Here lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent nec nisi nec elit volutpat sollicitudin. Sed cursus venenatis egestas. In mollis vehicula dictum. Sed id lacus vitae tortor commodo pharetra porttitor ut purus. Nullam euismod urna at felis accumsan sit amet viverra leo fermentum. Phasellus ac molestie sapien. In in neque purus. Cras eget lorem arcu. Aliquam ornare tellus vel nisi commodo molestie. Aliquam aliquet magna nisl. Quisque velit nulla, adipiscing ut sagittis id, luctus viverra leo. Nam nunc nisl, euismod eu dignissim nec, eleifend ut augue. Phasellus tempor condimentum ipsum, ut molestie lorem suscipit vel. Nulla luctus turpis eget neque facilisis eget sodales ante tincidunt. Praesent congue lobortis mollis. Maecenas non augue id mi dignissim luctus. Donec quis volutpat lectus. Mauris condimentum sodales luctus. Cras eget lorem arcu. Aliquam ornare tellus vel nisi commodo molestie. Aliquam aliquet magna nisl. Quisque velit nulla, adipiscing ut sagittis id, luctus viverra leo. Donec quis volutpat lectus. Mauris condimentum sodales luctus. Cras eget lorem arcu. Aliquam ornare tellus vel nisi commodo molestie. Aliquam aliquet magna nisl. Quisque velit nulla, adipiscing ut sagittis id, luctus viverra leo.
 
</div>
</div>
-
<div id="right" style="width:49%">
+
<img src="https://static.igem.org/mediawiki/2009/9/92/USALegislation.jpg" style="margin-left:-5px;margin-top:20px;">
-
<img src="http://www.scharfphoto.com/fine_art_prints/archives/199812-026-Staph-Bacteria.jpg" style="margin-left:10px;"width="370" height="300">
+
<div id="text" style="margin-left:20px;margin-top:10px;padding-bottom:15px;">
 +
The legislation covering the release of GMO’s in the USA is much less clearly defined with the main source of legislation being the 1986 “Coordinated Framework for Regulation of Biotechnology”. These laws were set up based on the assumption that biotechnology did not have any special or unique risks associated with it and hence it was covered by any previous laws which would govern similarly designed products but were produced by a more traditional approach. This has led to any release of GMO’s been looked at on a case by case basis.
 +
<br /><br />
 +
Since our system would essentially be an environmental release, in the US it would be covered under the “Toxic Substances Control Act" (TSCA), which is enforced by the US Environmental Protection Agency’s Office of Pollution Prevention and Toxics<sup>4</sup>. Further to this is would be subject to other legislation covering for example food and health as there is a possibility if the bacteria were released they could end up in the food chain and hence there could be a health implication. It is unclear as to which party would make the final decision on if a GMO would be approved for release.
 +
<br /><br />
 +
In the US some research has been carried out with releasing GMO’s in field; however this has only been done in galvanised steel silos with covered lids which were placed 3 m under the soil surface. This experiment was conducted this way as the scientist had to ensure that none of the GMO’s could be released to the environment for safety and environmental reasons. Since it was conducted in enclosed containers it does not give us a true representation of how the system would operate in practice but it is more realistic than carrying out the experiments in a lab based environment.
</div>
</div>
 +
 +
<img src="https://static.igem.org/mediawiki/2009/6/6e/LegislationConclusions.jpg" style="margin-left:-5px;margin-top:20px;">
 +
 +
<div id="text" style="margin-left:20px;margin-top:10px;padding-bottom:15px;">
 +
At the moment it is unclear as to whether our bacteria would be allowed to be released for use in landmine detection systems in either the UK or the US as there have been no preceding cases to judge this on. If permission was to be granted it is likely that bacteria would require some form of suicide mechanisms were it would only survive as long as necessary. For our system this is likely to be the length of time required for it to be seen and the location of the landmines marked, either physically or using some form of graphical representation.
</div>
</div>
-
<div id=bottomlinks align=right>
+
<img src="https://static.igem.org/mediawiki/2009/6/6a/ModellingReferences.jpg" style="margin-left:-5px;margin-top:20px;">
-
<div id=link><a href=#>next page</a></div>
+
 
-
<div id=link><a href=#>previous page</a></div>
+
<div id="text" style="margin-left:20px;margin-top:10px;padding-bottom:15px;">
-
</div>
+
<sup>1</sup><i>Pew Initiative of Food and Biotechnology,</i> “Guide of U.S Regulation of Genetically Modified Food and Agricultural Biotechnology Products” 2001<br /><br />
 +
<sup>2</sup><b>DEFRA, Department for environment, food and rural affairs,</b> “Draft: Deliberate release of genetically modified organisms: a guide” 2002 <br /><br />
 +
<sup>3</sup>http://www.defra.gov.uk/<br /><br />
 +
<sup>4</sup><b>Sayler,</b> G, Ripp, S, “Field applications of genetically engineered microorganisms for bioremediation processes”,<i> Current opinion in Biotechnology</i>, vol 11, 2000, p286-289.<br /><br />
 +
 
 +
</div>
 +
 
 +
 
 +
 
</div>
</div>
<div id=bottombox>
<div id=bottombox>

Latest revision as of 23:08, 21 October 2009

Our WIKI is best viewed with (click title):

* Internet Explorer 8
* Firefox 3
* Adobe Flash Player 10

If you encounter any visual problems please upgrade your browser to the latest version in order to get the most out of our WIKI. Thank you!
Underlying Philosophy - Legislation Issues
Personal note

I believe that science has a nasty trait of being condescending towards the general public. We, as scientists, often neglect our responsibilities and forget that we have a duty to involve others in our findings, from an political point of view (as it is the taxpayer who pays for basic research we conduct), as well as from an ethical point of view. I strongly believe that by keeping others in the dark we widen the gap between science and the general public. Of course, one could argue that the public has already had access to all our findings through journals and science articles—but I argue that this very claim is where the condescendence begins. A great part of involving people in what we do is the way we present scientific discoveries to them — a great example of good public communication of science would be an epigenetics pamphlet issued by Cancer Research UK I've recently seen. Although not everyone will be interested in it, we know that we have done our bit to make it accessible, and that is a very rewarding accomplishment in itself .

Julia
Since our system requires genetically modified bacteria to be released into the environment there are certain legal issues that must be reviewed before we can do this. In the UK the release of genetically modified organisms, GMO’s is covered under “The Genetically Modified Organisms (Deliberate Release) Regulations 2002”. This legislation covers all releases that are not subject to higher, more stringent legislation for example GM medicines. In the USA there is less clearly defined legislation for the release of GMO’s, which is still covered by the laws which were first adopted in 1986 to regulate against the products of biotechnology. This is done using federal agencies in the “Coordinated Framework for Regulation of Biotechnology”1
As previously stated the UK legislation on release of GMO’s is covered by “The Genetically Modified Organisms (Deliberate Release) Regulations 2002”. This legislation sets out all the steps which must be taken before any permission will be granted for the release of GMO’s. The legislation is split into 2 types of release, either a Part B or Part C release. A Part B release is one where the GMO is released for a non commercial application including for research purposes and a Part C release is for a commercial application. The decision making processes for these releases are slightly different with Part B applications being dealt with by the member EU state, in this case the UK, while Part C releases are dealt with at EU level, while also ensuring that local regulations are met. This means that all the countries in the EU have a say in any commercial release of GMO’s.

Before any GMO can be released to the environment it must go through the following stages of regulation :

• An application must be submitted to the Secretary of State.
• The application will then be scrutinised by independent scientific experts to ensure the safety standards of directive 2001/18 are met
• A public consultation is held
• A decision is taken by the regulators based on the expert advice and the public representations. If consent is granted, a list of conditions for the release will be included stating how the GMO may/may not be used.
• If the GMO is released, it will be monitored and if any new risks are discovered then the regulators have the right to amend of revoke the consent.

There are slight differences in the way that Part B and Part C releases are dealt with and these are shown in the following Gantt charts shown in Figure 1 and Figure 2.

Figure 1: Gantt chart showing the different stages required before a Part B release will be approved.


Figure 2: Gantt chart showing the different stages required before a Part C release will be approved.


Since one of the steps in this both Part B and Part C releases require a public consultaion to be held before any approval would be made we decided that it would be interesting to conduct our own survey to find out the public perception on both our system and on synthetic biology in general. The survey results can be found here.

From the information given on the “Department for Environment, Food and Rural Affairs”, DEFRA, website , no release of GMO bacteria for a similar purpose to ours had been approved however there was no information to indicate if any attempt had been made. This is to say that we are unsure about how the UK authorities would react to our system.
The legislation covering the release of GMO’s in the USA is much less clearly defined with the main source of legislation being the 1986 “Coordinated Framework for Regulation of Biotechnology”. These laws were set up based on the assumption that biotechnology did not have any special or unique risks associated with it and hence it was covered by any previous laws which would govern similarly designed products but were produced by a more traditional approach. This has led to any release of GMO’s been looked at on a case by case basis.

Since our system would essentially be an environmental release, in the US it would be covered under the “Toxic Substances Control Act" (TSCA), which is enforced by the US Environmental Protection Agency’s Office of Pollution Prevention and Toxics4. Further to this is would be subject to other legislation covering for example food and health as there is a possibility if the bacteria were released they could end up in the food chain and hence there could be a health implication. It is unclear as to which party would make the final decision on if a GMO would be approved for release.

In the US some research has been carried out with releasing GMO’s in field; however this has only been done in galvanised steel silos with covered lids which were placed 3 m under the soil surface. This experiment was conducted this way as the scientist had to ensure that none of the GMO’s could be released to the environment for safety and environmental reasons. Since it was conducted in enclosed containers it does not give us a true representation of how the system would operate in practice but it is more realistic than carrying out the experiments in a lab based environment.
At the moment it is unclear as to whether our bacteria would be allowed to be released for use in landmine detection systems in either the UK or the US as there have been no preceding cases to judge this on. If permission was to be granted it is likely that bacteria would require some form of suicide mechanisms were it would only survive as long as necessary. For our system this is likely to be the length of time required for it to be seen and the location of the landmines marked, either physically or using some form of graphical representation.
1Pew Initiative of Food and Biotechnology, “Guide of U.S Regulation of Genetically Modified Food and Agricultural Biotechnology Products” 2001

2DEFRA, Department for environment, food and rural affairs, “Draft: Deliberate release of genetically modified organisms: a guide” 2002

3http://www.defra.gov.uk/

4Sayler, G, Ripp, S, “Field applications of genetically engineered microorganisms for bioremediation processes”, Current opinion in Biotechnology, vol 11, 2000, p286-289.

Edinburgh University iGEM Team 2009